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There has been a signiﬁcant increase in the number of patients receiving cardiovascular implantable
electronic devices (CIED) over the last two decades. CIED infection represents a serious complication
after CIED implantation and is associated with signiﬁcant morbidity and mortality. Recently, newly
advanced technologies have offered attractive and suitable therapeutic alternatives. Notably, the leadless
pacemaker and anti-bacterial envelope decrease the potential risk of CIED infection and the resulting
mortality, when it does occur. A completely subcutaneous implantable cardioverter deﬁbrillator is also an
alternative to the transvenous implantable cardioverter deﬁbrillator (ICD), as it does not require
implantation of any transvenous or epicardial leads. Among the patients who require ICD removal and
subsequent antibiotics secondary to infection, the wearable cardioverter deﬁbrillator represents an
alternative approach to inpatient monitoring for the prevention of sudden cardiac death. In this review
paper, we aimed to introduce the advanced technologies and devices for prevention of CIED infection.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
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There has been a signiﬁcant increase in the number of patients
receiving cardiovascular implantable electronic devices (CIED) overblished by Elsevier B.V. This is an
ine-Cardiology, University of
Kondo).the last two decades [1,2]. This is largely owing to the expanding
indications of CIED based on technological improvements and new
evidence demonstrating improved survival and quality of life among
certain groups of patients having structural heart diseases [3,4].
However, the advantage of these devices is limited by associated
adverse events and complications. CIED infection represents a serious
complication of cardiac device therapy and is associated with sig-
niﬁcant morbidity and mortality. Despite appropriate care, in-hospitalopen access article under the CC BY-NC-ND license
Fig. 1. A case of cardiac implantable electronic device infection.
Fig. 2. The Nanostim™ Leadless Pacemaker (St Jude Medical, Inc., St. Paul, MN,
USA) Reprinted with permission from St Jude Medical, Inc.
Fig. 3. The Micra™ Transcatheter Pacing System (Medtronic plc). Reprinted with
permission from Medtronic plc.
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from 4% to 10% and one-year mortality from 15% to 20% [5–11].
The majority of patients with CIED infection have pocket and/or
endovascular lesions (Fig. 1). If aggressive antibiotic therapy fails to
control CIED infection, then complete removal of the device is
recommended in many instances [2,6]. The timing of re-
implantation is another critical issue. An early re-implantation
should be performed in patients who are solely dependent on the
CIED; however, at least one week is required to control local or
systemic bacterial infections [12]. Currently, the advanced tech-
nologies may contribute to a decrease in infection risk and mor-
tality and may bridge the critical period between device removal
and re-implantation.2. New technologies to reduce the risk of CIED infection
In the USA and Europe, some new alternatives to prevent CIED
infection are available. The leadless pacemaker and antibacterial
envelope represent attractive and suitable therapeutic options to
minimize the risk of CIED infection.
2.1. Leadless pacemaker
To reduce the complications associated with the standard
transvenous electrode lead of the pacemaker, a leadless pacemaker
has been invented. The concept of a completely self-contained VVIR
intracardiac pacemaker, ﬁrst explored about 45 years ago by
Spickler JW et al., has ﬁnally become a reality with the development
of the Nanostim™ Leadless Pacemaker (St Jude Medical, Inc., St.
Paul, MN, USA) and the Micra™ Transcatheter Pacing System
(Medtronic plc) for use in humans [13–16]. Technological advances
in electronics miniaturization and battery chemistries have enabled
creation of a device small enough to be implanted within the heart
via a percutaneous, transvenous approach, while still providing
similar battery longevity without leads. The leadless pacemaker has
been expected to reduce CIED infections, because this system has no
physical connection between the endocardium and the sub-
cutaneous pocket, which are the most likely source and channel of
bacterial infection, respectively. Furthermore the leadless stand-
alone system never produces subclavian or supra vena-cava occlu-
sions. Both systems have received the CE Mark in Europe, but are
not approved in the USA.
The Nanostim system is delivered to the implant site at the
lower septum of the right ventricle (RV) via a transfemoral route
and allows for bradycardia pacing via a miniature pulse generator
with a built-in battery and electrodes that can be entirely and
permanently implanted (Fig. 2). The ﬁrst successful Nanostim
implantation in humans took place in December 2012 in Prague,
Czech Republic. Recently, a nonrandomized ﬁrst-in-human studydemonstrated this system to be safe and feasible over a 90-day
period [15]. This preclinical study expanded on the previous study
by demonstrating that the pacing and sensing properties remain
adequate for up to 18 months. In addition, the histological analyses
at the 90-day mark revealed a limited local response to the
implanted device at the RV apex. Furthermore, there were no
signiﬁcant adhesions between the device and the RV walls. These
pathological features may have important implications related to
the long-term efﬁcacy and safety of this system, as well as for
designing approaches to extract the device.
The Micra system, similar to the Nanostim system, is an inves-
tigational device and is being assessed in a pivotal global clinical
trial. The miniaturized device is only one-tenth the size of a con-
ventional pacemaker (Fig. 3). The Micra system is also delivered
directly into the heart through a catheter inserted in the femoral
vein. Once positioned, the pacemaker is securely attached to the
heart wall in the RV and can be repositioned or retrieved during
implantation if needed (Fig. 4). The device does not require the use
of leads and is attached via small tines securing it to the heart wall.
The ﬁrst successful in-human Micra implantation occurred in
December 2013 in Linz, Austria. It is currently being evaluated in the
Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical
Trial, which is a single-arm, multicenter study that will enroll up to
780 patients at approximately 50 centers [16].
Both systems allow for retrievability, if needed; however, there
are signiﬁcant differences in the designs that are worth noting: (i) the
Micra device has an active ﬁxation mechanism consisting of four
electrically-inactive extendable and retractable tines to anchor it to
the cardiac tissue, whereas the Nanostim device uses an electrically
active ﬁxed helix, (ii) the Micra device is wider (20 Fr) and shorter
(25.9 mm) than the Nanostim pacemaker (18 Fr and 41.4 mm), (iii)
the Micra pacemaker's communication between the device and
programmer is established using a standard programming head,
whereas the Nanostim pacemaker communicates with the St. Jude
Medical Merlin™ Patient Care System using a programmer link and
surface electrocardiographic electrodes, and (iv) the Micra device
Fig. 4. Micra inside the right ventricle. Reprinted with permission from Medtronic plc.
Fig. 5. The TYRX™ Antibacterial Envelope (Medtronic plc). Reprinted with per-
mission from Medtronic plc.
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Nanostim pacemaker utilizes a blood temperature sensor.
The most relevant limitation is that the current Nanostim and
Micra devices are indicated for patients requiring a single-
chamber pacemaker only, limiting their use to a relatively small
percentage of patients. Current indications focus on patients with
chronic atrial ﬁbrillation and second- or third-degree atrioven-
tricular block, patients with sinus rhythm with second- or third-
degree atrioventricular block and a low level of physical activity or
short expected lifespan, and patients with sinus bradycardia with
infrequent pauses or unexplained syncope.
2.2. Anti-bacterial envelope
Previously published randomized controlled studies indicate
that perioperative intravenous administration of a cephalosporin
antibiotic can help to reduce CIED infections [2,18]. The European
Society of Cardiology, American Heart Association, and Heart
Rhythm Society recommendations for prophylaxis at the time of
CIED placement consist of an antibiotic that has in-vitro activity
against staphylococci. In recent large studies, the vast majority of
patients received antimicrobial prophylaxis with CIED placement
[19,20]. Despite widespread use of antimicrobial prophylaxis, CIED
infection rates are increasing faster than implantation rates [21].
Effective antimicrobial prophylaxis could help reduce CIED infec-
tions and improve clinical outcomes.
The TYRX™ Antibacterial Envelope (Medtronic plc) consists of a
Food and Drug Administration (FDA)-approved surgical mesh
envelope that releases minocycline and rifampicin in the generator
pocket after implantation with a CIED (Fig. 5) [17]. The biocompa-
tible mesh is coated with antibiotics that elute (dissolve) within an
approximately 7-day period. The TYRX™ is of two types, with
substrate meshes that are 100% absorbable or non-absorbable. A
recent report suggests that the use of the TYRX™ absorbable
envelope was associated with a very low prevalence (0%) of CIED-
related infections that was comparable to that seen with the non-
absorbable envelope. However, data from a randomized clinical trial
are needed to support increased use of the antibacterial envelope
[22]. Both TYRX™ Antibacterial Envelopes are sterile devices con-
structed of an open-pore weave, knitted ﬁlaments of a lightweight
mesh, and an absorbable polymer coating impregnated with anti-
microbial agents. The antibacterial envelope is indicated for holdingCIEDs, thereby creating a stable environment surrounding the
device and leads after surgical placement.
At least one-half to two-thirds of CIED infections are caused by
Staphylococcus aureus (S. aureus) and coagulase-negative staphylo-
coccus species (CoNS) [18,20,23–25]. In vitro, methicillin-resistant
strains of S. aureus and many strains of CoNS are susceptible to a
combination of two antibiotics with distinct mechanisms of actions:
minocycline and rifampicin [26–28]. Rifampicin is bacteriostatic
and inhibits DNA-dependent RNA polymerase. Minocycline is bac-
teriostatic and inhibits protein synthesis. Minocycline has an anti-
microbial spectrum against a wide range of gram-positive and
gram-negative organisms. Rifampin is a semi-synthetic compound
derived from Amycolatopsis rifamcinica and has antimicrobial
activity against select gram-positive and gram-negative organisms.
The substrate mesh varies between the two types of envelopes and
consists of either polypropylene or Glycoprene II. Polypropylene has
been utilized in surgically implanted medical devices for decades.
The most common use is in hernia repairs.
The absorbable tyrosine-based polymer coating is designed to
degrade to well-characterized natural metabolites. It has been
demonstrated to resorb benignly, in the same manner as absorbable
surgical sutures, while eliciting a minimal inﬂammatory response. It
also has a long history of use with other FDA-approved implantable
medical devices. Randomized controlled trials demonstrated that
coating or impregnating catheters with the combination of rifampin
and minocycline signiﬁcantly reduces device-associated infections
of central venous, hemodialysis, and cerebrospinal ﬂuid drain
catheters, especially infections with S. aureus and CoNS [29–35].
Preclinical studies demonstrated that the antibacterial envel-
ope helped reduce the risk for infection by several pathogens,
including Staphylococcus epidermidis, within CIED implant pockets
[36]. A previous large clinical study indicated that the envelope is
associated with a high rate of successful CIED implantation and a
low risk of infection in a population at signiﬁcant risk for CIED
infection. Furthermore, standard use of an antibacterial envelope
was associated with a signiﬁcantly lower rate of CIED infection and
appeared to be economically viable [37].3. New technology for prevention of fatal CIED infection
It is widely accepted that complication rates are higher with re-
implantations, particularly if a lead implantation or revision is
involved [38,39]. In addition, morbidity and mortality is particu-
larly high in patients with an infected transvenous implantable
Fig. 6. The entirely subcutaneous ICD system (EMBLEM™ S-ICD System, Boston
Scientiﬁc Corp., Marlborough, MA, USA). Image provided courtesy of Boston Sci-
entiﬁc. © 2015 Boston Scientiﬁc Corporation or its afﬁliates. All rights reserved.
Fig. 7. The entirely subcutaneous ICD system with the pulse generator implanted
subcutaneously in a left lateral position and the parasternal lead-electrode posi-
tioned parallel to and 1 to 2 cm to the left of the sternal midline. The lead-electrode
contains 2 sensing electrodes separated by an 8 cm shocking coil. Image provided
courtesy of Boston Scientiﬁc. © 2015 Boston Scientiﬁc Corporation or its afﬁliates.
All rights reserved.
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when a systemic infection or endocarditis is present.
The risk of reinfection following system re-implantation is also
a concern [40,41].
A completely subcutaneous ICD was developed as an alternative to
the transvenous-ICD system, as it is implanted without any transve-
nous or epicardial leads. The rate of infections resulting in explanta-
tion or revision of this new device was not lower than that reported
in previous ICD registries. However, it should be emphasized that
none of the documented device infections were systemic [42].
3.1. Complete subcutaneous implantable cardioverter deﬁbrillator
The completely subcutaneous ICD system (S-ICD™ System,
Boston Scientiﬁc Corp., Marlborough, MA, USA) was developed to
provide life-saving deﬁbrillation therapy while leaving the heart
and vasculature untouched [43]. The S-ICD system is preferred over
transvenous-ICD for patients having no vascular access, a history of
recurrent transvenous lead infections, or primary electrical disease
with ventricular ﬁbrillation as the major life-threatening rhythm.
The ﬁrst pilot-phase human studies of the S-ICD commenced in
2008, followed by subsequent regulatory and post-marketing stu-
dies. Approved by the FDA in September 2012, to provide deﬁ-
brillation therapy for the treatment of ventricular tachyarrhythmias,
the S-ICD system was developed after 10 years of deﬁbrillation and
sensing research, acute human feasibility studies, and long-term
clinical studies [43–49]. This system demonstrated a very high
shock efﬁcacy for spontaneous ventricular arrhythmias and a
decreased incidence of inappropriate shocks [48].
The S-ICD system is comprised of a pulse generator, subcutaneous
electrode, electrode-insertion tool, and device programmer. The pulse
generator has an estimated longevity of 5 years and is slightly larger
with a weight (145 g) approximately double that of a modern trans-
venous ICD generator [49]. It provides high-energy deﬁbrillation shock
(80 J) therapy through the use of a constant-tilt biphasic form. In
addition, the new generation S-ICD System (EMBLEM™ [Fig. 6]),
which is 20% thinner and is projected to last 40% longer than the
previous S-ICD system, is available in a small number of centers in
Europe and USA. This system is also enabled for remote patient
management for increased patient convenience. The generator is
placed subcutaneously in a left lateral position over the 6th rib
between the midaxillary and anterior axillary lines. Via two para-
sternal incisions, a 3 mm tripolar parasternal electrode (polycarbonate
urethane) is positioned parallel to and 1 to 2 cm to the left of the
sternal midline with the distal sensing electrode localized adjacent to
the manubriosternal junction and the proximal sensing electrode
positioned adjacent to the xiphoid process (Fig. 7).
A population-based decrease in mortality with a new device is
paramount, but can be negated if the implant is associated with a
higher risk of removal due to pocket infection. Infection without any
bacteremia remained the most common complication requiringinvasive action in the early experience with the S-ICD [44–46]. Many
steps were taken to mitigate this risk and prevent device removal,
including better operative preparation training and techniques and
aggressive management of skin infections [45]. Advances in
implantation techniques were introduced in the literature by Knops
et al. in an effort to reduce the incisional surface area and resulting
infection risk [50]. Advances in operator experience, preparation, and
implantation techniques appear to have positively affected the rates
of infection, as use of the S-ICD system has expanded worldwide. In
recent studies, the simplicity of implantation which avoids vascular
access was reﬂected in the very low rate (2%) of acute major com-
plications such as device system infection [48]. The S-ICD could be a
new alternative to the conventional transvenous-ICD system to
minimize device system infections.
The limitations of the current S-ICD include its inability to pro-
vide anti-tachycardia pacing for ventricular tachycardia, limited
bradycardia pacing support, and absence of endovascular monitor-
ing capabilities for collateral data gathering such as impedance
monitoring for chronic heart failure. One estimate of potential
candidates for the S-ICD includes every patient indicated for pri-
mary SCD prevention without a pacing indication. In addition, the
use of a subcutaneous sensing electrode with the S-ICD may theo-
retically increase the risk of over-sensing noise or myopotential
signals and under-sensing low-amplitude cardiac signals during
ventricular ﬁbrillation. The previous trial compared the arrhythmia
detection of 3 commercially available transvenous ICD lead systems
with the S-ICD electrode [51]. All devices excelled in detecting
ventricular tachyarrhythmia (100%); however, the S-ICD demon-
strated greater speciﬁcity in discriminating supraventricular from
ventricular tachycardia (98% S-ICD vs. 76.7% single-chamber trans-
venous-ICD vs. 68% dual-chamber transvenous-ICD). Ideally, greater
user programming experience and improvements in S-ICD tech-
nology may reduce the rate of inappropriate shocks.4. New technology to reduce the risk of sudden cardiac death
after the removal of ICD: a wearable cardioverter deﬁbrillator
ICD therapy has been established as a cornerstone of cardiology
practice for reducing the incidence of SCD [52–55]. Unfortunately,
ICD system infection represents a complication that occurs even in
experienced centers. Among patients who require ICD removal and
subsequent antibiotic therapy, a wearable cardioverter deﬁbrillator
(WCD; LifeVest WCD4000, ZOLL, Pittsburgh, PA, USA) represents an
alternative approach to prevention of SCD. Removal of the ICD
deprives the patient of the protection against potential life-
threatening ventricular tachyarrhythmias, particularly in patients
with ICD implantation for secondary prevention of SCD. The Heart
Fig. 8. The wearable cardioverter deﬁbrillator (LifeVest WCD4000, ZOLL, Pittsburgh,
PA, USA). Adopted from ZOLL homepage (http://lifevest.zoll.com/).
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implantation when the ongoing infection is a concern [56].
The WCD was introduced into clinical practice in 2002, and
indications for its use are expanding currently. It has been in use
worldwide, especially in the USA and Germany [57,58].
This device consists of an external deﬁbrillator vest that auto-
matically detects and treats ventricular tachyarrhythmias without
bystander assistance [59,60]. A WCD is composed of a garment
containing two deﬁbrillation patch electrodes on the back, an
elastic belt with a front-deﬁbrillation patch electrode, and four
non-adhesive ECG electrodes connected to a monitoring and
deﬁbrillation unit (Fig. 8). Recent trials demonstrated the efﬁcacy
of the WCD in the detection and treatment of lethal ventricular
arrhythmias [57,61]. The WCD therapy can prevent SCD until ICD
re-implantation is feasible in patients who underwent device
removals for device system infections [62].
The efﬁcacy of the WCD in the prevention of arrhythmic SCD
would seem to be highly dependent on patient compliance. Proper
instruction on the use of WCD is also important to avoid inappropriate
shocks. In previous studies, inappropriate shock is a rare event that
occurs in 0–3% of patients using WCD [63,64]. Shocks may be inap-
propriately delivered due to noise, device malfunction, or the rate
criteria. A WCD is a unique tool designed to avoid unnecessary shock
therapy. If a persistent arrhythmia is detected, the WCD notiﬁes the
patient via a “responsiveness test,” allowing a conscious patient to
prevent treatment. A conscious patient can hold the “response but-
tons” during the “responsiveness test” to prevent an unnecessary
treatment. Therefore, much attention is being paid to the provision of
medical education and information to patients in order to optimize
their understanding and acceptance of the WCD therapy [59].
The strategy for re-implantation after removal of an ICD must
be individualized to each patient and clinical situation. For many
patients, continuous inpatient/outpatient monitoring may be
impossible or at least highly undesirable. The WCD is a cost-
effective alternative to protect patients against SCD following the
removal of an infected ICD while waiting for ICD re-implantation,
as compared to keeping patients in the hospital or discharging
them to go home or to a skilled nursing facility [12].5. Conclusion
CIED system infection represents a relevant complication after
CIED implantation and is associated with a signiﬁcant risk ofmorbidity and mortality. However, newly developed technologies
and devices represent attractive and suitable therapeutic options
to reduce the incidence of this increasing problem.Conﬂict of interest
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